Renaissance Technologies’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.55M | Sell |
1,833,128
-1,760,005
| -49% | -$2.42M | ﹤0.01% | 1757 |
|
|
2025
Q4 | $5.78M | Sell |
3,593,133
-359,594
| -9% | -$753K | 0.01% | 1212 |
|
|
2025
Q3 | $10.8M | Sell |
3,952,727
-241,700
| -6% | -$804K | 0.01% | 1060 |
|
|
2025
Q2 | $15.3M | Buy |
4,194,427
+188,600
| +5% | +$518K | 0.02% | 838 |
|
|
2025
Q1 | $7.69M | Buy |
4,005,827
+182,300
| +5% | +$372K | 0.01% | 1156 |
|
|
2024
Q4 | $7.26M | Buy |
3,823,527
+105,727
| +3% | +$184K | 0.01% | 1208 |
|
|
2024
Q3 | $4.91M | Sell |
3,717,800
-197,000
| -5% | -$263K | 0.01% | 1454 |
|
|
2024
Q2 | $3.99M | Buy |
3,914,800
+262,700
| +7% | +$325K | 0.01% | 1452 |
|
|
2024
Q1 | $6.68M | Sell |
3,652,100
-1,127,283
| -24% | -$1.8M | 0.01% | 1228 |
|
|
2023
Q4 | $5.93M | Buy |
4,779,383
+1,623,956
| +51% | +$1.66M | 0.01% | 1243 |
|
|
2023
Q3 | $3.6M | Sell |
3,155,427
-175,300
| -5% | -$225K | 0.01% | 1485 |
|
|
2023
Q2 | $3.05M | Buy |
3,330,727
+992,227
| +42% | +$958K | ﹤0.01% | 1732 |
|
|
2023
Q1 | $1.31M | Sell |
2,338,500
-547,727
| -19% | -$418K | ﹤0.01% | 2290 |
|
|
2022
Q4 | $1.67M | Sell |
2,886,227
-130,200
| -4% | -$40.8K | ﹤0.01% | 2193 |
|
|
2022
Q3 | $954K | Buy |
3,016,427
+1,534,127
| +103% | +$602K | ﹤0.01% | 2527 |
|
|
2022
Q2 | $523K | Buy |
1,482,300
+478,973
| +48% | +$201K | ﹤0.01% | 3139 |
|
|
2022
Q1 | $720K | Buy |
1,003,327
+380,300
| +61% | +$814K | ﹤0.01% | 2949 |
|
|
2021
Q4 | $1.41M | Sell |
623,027
-326,900
| -34% | -$891K | ﹤0.01% | 2412 |
|
|
2021
Q3 | $2.74M | Sell |
949,927
-877,803
| -48% | -$2.51M | ﹤0.01% | 1862 |
|
|
2021
Q2 | $6.93M | Buy |
1,827,730
+757,149
| +71% | +$2.55M | 0.01% | 1428 |
|
|
2021
Q1 | $3.62M | Sell |
1,070,581
-377,346
| -26% | -$1.36M | ﹤0.01% | 1847 |
|
|
2020
Q4 | $4.05M | Buy |
1,447,927
+1,377,752
| +1,963% | +$4.02M | ﹤0.01% | 1721 |
|
|
2020
Q3 | $176K | Sell |
70,175
-5,514
| -7% | -$48.4K | ﹤0.01% | 3133 |
|
|
2020
Q2 | $1.03M | Buy |
+75,689
| New | +$783K | ﹤0.01% | 2522 |
|
|
2020
Q1 | – | Sell |
-138,527
| Closed | -$875K | – | 3415 |
|
|
2019
Q4 | $875K | Buy |
138,527
+95,100
| +219% | +$452K | ﹤0.01% | 2691 |
|
|
2019
Q3 | $170K | Buy |
+43,427
| New | +$186K | ﹤0.01% | 3184 |
|
|
2018
Q4 | – | Sell |
-1,776,971
| Closed | -$15.7M | – | 3355 |
|
|
2018
Q3 | $15.7M | Sell |
1,776,971
-97,629
| -5% | -$873K | 0.02% | 1078 |
|
|
2018
Q2 | $18.7M | Sell |
1,874,600
-644,500
| -26% | -$6.45M | 0.02% | 961 |
|
|
2018
Q1 | $24M | Buy |
2,519,100
+697,900
| +38% | +$9.76M | 0.03% | 835 |
|
|
2017
Q4 | $27.1M | Buy |
1,821,200
+400,300
| +28% | +$6.64M | 0.03% | 753 |
|
|
2017
Q3 | $27.9M | Buy |
1,420,900
+395,600
| +39% | +$6.08M | 0.03% | 696 |
|
|
2017
Q2 | $14.7M | Buy |
1,025,300
+639,033
| +165% | +$8.1M | 0.02% | 1023 |
|
|
2017
Q1 | $3.55M | Buy |
386,267
+177,667
| +85% | +$1.73M | 0.01% | 1912 |
|
|
2016
Q4 | $2.17M | Buy |
208,600
+56,800
| +37% | +$489K | ﹤0.01% | 2183 |
|
|
2016
Q3 | $1.37M | Buy |
151,800
+127,500
| +525% | +$1.08M | ﹤0.01% | 2410 |
|
|
2016
Q2 | $182K | Sell |
24,300
-4,200
| -15% | -$36.7K | ﹤0.01% | 3070 |
|
|
2016
Q1 | $257K | Sell |
28,500
-80,700
| -74% | -$654K | ﹤0.01% | 3017 |
|
|
2015
Q4 | $1.41M | Sell |
109,200
-1,500
| -1% | -$15.3K | ﹤0.01% | 2303 |
|
|
2015
Q3 | $1.07M | Sell |
110,700
-270,539
| -71% | -$2.48M | ﹤0.01% | 2344 |
|
|
2015
Q2 | $3.92M | Buy |
+381,239
| New | +$3.25M | 0.01% | 1605 |
|
Other funds holding AKBA
VCM
VPM
Renaissance Technologies's AKBA Position: Q1 2026 in Review
Renaissance Technologies reduced its Akebia Therapeutics (AKBA) stake by 49% in Q1 2026, selling an estimated $2.42M and leaving 1,833,128 shares worth $2.55M. The position accounts for ﹤0.01% of the portfolio, ranked #1757.
Renaissance Technologies first reported a position in AKBA in Q2 2015 and has held it in 40 quarters since. The position peaked at $27.9M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Renaissance Technologies held 1,833,128 shares of Akebia Therapeutics worth $2.55M as of Q1 2026.
- Renaissance Technologies sold 1,760,005 Akebia Therapeutics shares in Q1 2026, an estimated $2.42M.
- Akebia Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #1757 holding.
- Renaissance Technologies first reported a position in Akebia Therapeutics in Q2 2015 and has held it in 40 quarters since.
- Renaissance Technologies's Akebia Therapeutics position peaked at $27.9M in Q3 2017.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.